| Deal Title |
Date Announced |
Stage |
Type |
Primary Therapeutic Area |
Primary Indication |
Primary Tech |
Article |
| Diligent Health purchasing Diplomat’s business unit |
10.16.19 |
10 Not Applicable |
Business Unit Purchase |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Hsiri development and commercialization deal with Shionogi |
10.11.19 |
01 Platform / Discovery |
Dev and Commercial |
Infectious |
Mycrobacterium |
Small Molecule |
Link |
| Aclaris commercialization deal with EPI Health |
10.10.19 |
06 Approved |
Sales / Co-Promotion |
Dermatologic |
Rosaceo |
Small Molecule |
Link |
| ONE HUNDRED contract service deal with Gobel Group |
10.07.19 |
10 Not Applicable |
Contract Service |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Context Therapeutics clinical trial collaboration with Wisconsin Oncology Network |
10.07.19 |
04 Phase II |
University/Foundation |
Cancer |
Breast Cancer |
Small Molecule |
Link |
| CHOP development and commercialization deal with Tmunity |
10.01.19 |
09 Not Disclosed |
Dev and Commercial License |
Cancer |
Cancer (General) |
Immunotherapy / Cell Therapy |
Link |
| OptiNose commercialization deal with Currax |
9.26.19 |
06 Approved |
Sales / Co-Promotion Only |
Neurologic |
Migraine |
Small Molecule |
Link |
| NIH grant to Knoop |
9.26.19 |
01 Platform / Discovery |
University / Foundation |
Other |
Pain |
Other Tech |
Link |
| Eisai co-promotion deal with Mylan |
9.20.19 |
06 Approved |
Sales / Co-Promotion Only |
Cancer |
Cancer (General) |
Small Molecule |
Link |
| Context clinical trial agreement with Jefferson Health |
9.19.19 |
04 Phase II |
R&D Only |
Cancer |
Endometrial cancer |
Formulation – Oral |
Link |
| NIH grant to Inovio Pharmaceuticals |
9.17.19 |
02 Preclinical / IND |
University / Foundation |
Infectious |
Bacterial Infection |
Biologic (General) |
Link |
| Penn State Health purchasing ViewRay’s system |
9.16.19 |
01 Platform / Discovery |
Platform, Product Purchase |
Cancer |
Cancer (General) |
Unknown |
Link |
| Context Therapeutics clinical trial agreement with SOLTI |
9.16.19 |
04 Phase II |
University / Foundation |
Cancer |
Breast Cancer |
Other Tech |
Link |
| Oncora research partnership with Varian Medical |
9.13.19 |
09 Not Disclosed |
R&D Only |
Cancer |
Cancer (General) |
Other Tech |
Link |
| Castle Creek acquiring Fibrocell |
9.12.19 |
06 Approved |
Acquisition |
Dermatologic |
Genetic diseases |
Small Molecule |
Link |
| HIG Capital acquiring BioVectra |
9.10.19 |
10 Not Applicable |
Acquisition |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Phio Pharma research partnership with Carisma Therapeutics to develop immunotherapy |
9.09.19 |
01 Platform / Discovery |
R&D Only |
Cancer |
Cancer (General) |
Immunotherapy / Cell Therapy |
Link |
| MDA grant to Thomas Jefferson University |
9.05.19 |
09 Not Disclosed |
University / Foundation |
Neurologic |
Amyotrophic lateral sclerosis (ALS) |
Gene Therapy |
Link |
| IMV research partnership with the Wistar Institute |
9.04.19 |
01 Platform / Discovery |
University / Foundation |
Cancer |
Non-Hodgkin’s lymphoma (NHL) |
Immunotherapy / Cell Therapy |
Link |
| Lannett contract service deal with Cediprof |
8.27.19 |
06 Approved |
Contract Service |
Cancer |
Cancer (General) |
Unknown |
Link |
| Genomind contract service deal with NeuroFlow |
8.19.19 |
09 Not Disclosed |
Contract Service |
Other |
Other |
Other Tech |
Link |
| Q-State research partnership 2bPrecise to develop clinical-genomic datasets |
8.13.19 |
10 Not Applicable |
R&D Only |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Mission clinical trial agreement with Onconova to evaluate rigosertib |
8.12.19 |
01 Platform / Discovery |
R&D Only |
Cancer |
Cancer (General) |
Small Molecule |
Link |
| Penn research partnership with AC Immune for neurodegenerative diseases |
8.12.19 |
01 Platform / Discovery |
University / Foundation |
Neurologic |
Amyotrophic lateral sclerosis (ALS) |
Protein |
Link |
| AstraZeneca license option deal with Aevi for MEDI2338 |
8.07.19 |
04 Phase II |
Option to license |
Inflaation |
Inflammatory disease |
Antibody |
Link |
| BioIVT acquiring Keystone Biologicals |
8.06.19 |
10 Not Applicable |
Acquisition |
Not Applicable |
Not Applicable |
Diagnostic-Other |
Link |
| TerrAscend acquiring Ilera Healthcare |
8.02.19 |
10 Not Applicable |
Acquisition |
Not Applicable |
Not Applicable |
Other Tech |
Link |
| Bigfoot Biomedical research partnership with Allegheny Health Network |
8.01.19 |
07 Device – Any |
R&D Only |
Endocrine/Metabolic |
Diabetes |
Device (General) |
Link |
| Pfizer’s generics business Upjohn merged with Mylan in a Reverse Morris Trust transaction |
7.29.19 |
06 Approved |
Acquisition |
Autoimmune |
Allergy |
Small Molecule |
Link |
| Helomics research partnership with UPMC for ovarian cancer |
7.18.19 |
01 Platform / Discovery |
University / Foundation |
Cancer |
Ovarian Cancer |
Other Tech |
Link |
| Medial EarlySign research partnership with Geisinger to develop machine learning-based solutions |
7.10.19 |
01 Platform / Discovery |
R&D Only |
Gastrointestinal |
Gastrointestinal |
Other Tech |
Link |
| Celsius research partnership with Janssen Biotech to identify response biomarkers for ulcerative colitis |
7.09.19 |
01 Platform / Discovery |
R&D Only |
Gastrointestinal |
Colitis |
Sequencing |
Link |
| AmerisourceBergen contract service with OneOncology |
7.08.19 |
10 Not Applicable |
Contract Service |
Cancer |
Cancer (General) |
Stem Cell |
Link |
| Versant Ventures formed Century Therapeutics |
7.01.19 |
01 Platform / Discovery |
Company Formation |
Cancer |
Hematologic malignancies |
Stem Cell |
Link |
| Fujifilm development and commercialization deal Century Therapeutics for iPSC platform |
7.01.19 |
01 Platform / Discovery |
Dev and Commercial License |
Cancer |
Cancer (General) |
Stem Cell |
Link |
| GD3 acquiring NexusPharma |
6.18.19 |
09 Not Disclosed |
Acquisition |
Cancer |
Cancer (General) |
Other Tech |
Link |
| Tekni-Plex purchasing Amcor’s three manufacturing facility |
6.17.19 |
10 Not Applicable |
Facility Purchase |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Orchestra development and commercialization deal with Terumo for Virtue SEB |
6.13.19 |
07 Device – Any |
Dev and Commercial |
Other |
Percutaneous coronary intervention (PCI) |
Device (General) |
Link |
| Genmab research partnership with Janssen with an option to license HexaBody-CD3 |
6.11.19 |
01 Platform / Discovery |
Option to License |
Cancer |
Multiple myeloma (MM) |
Antibody |
Link |
| DTRA grant to Inovio |
6.10.19 |
07 Device-Any |
University/Foundation |
Unknown |
Not Applicable |
Device (General) |
Link |
| University of Pennsylvania research partnership with Amicus to develop gene therapy |
5.29.19 |
01 Platform / Discovery |
University / Foundation |
Endocrine/Metabolic |
Metabolic (General) |
Gene Therapy |
Link |
| Ilera development and commercialization deal with Ethicann for CAN-001 |
5.22.19 |
09 Not Disclosed |
Dev and Commercial License |
Cancer |
Cancer (General) |
Other Tech |
Link |
| LifeScan commercialization deal with Sanvita for Continuous Glucose Monitoring (CGM) Devices |
5.21.19 |
07 Device – Any |
Sales / Co-Promotion Only |
Endocrine / Metabolic |
Diabetes |
Device (General) |
Link |
| JPMorgan Chase acquiring InstaMed |
5.17.19 |
10 Not Applicable |
Acquisition |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Inovio research partnership with Qiagen to co-develop companion diagnostic |
5.16.19 |
08 Diagnostic – Any |
R&D Only |
Cancer |
Cervical Dysplasia |
Diagnostic – Companion |
Link |
| Onconova development and commercialization deal with HanX for Rigosertib |
5.13.19 |
05 Phase III |
Dev and Commerical |
Hematologic |
Myelodysplastic Syndrome (MDS) |
Small Molecule |
Link |
| Tmunity license deal with UCSF for TCR T cell therapy |
5.01.19 |
02 Preclinical / IND |
University / Foundation |
Cancer |
Cancer (General) |
Immunotherapy / Cell Therapy |
Link |
| Sensus research partnership with the University of Pennsylvania for IORT system |
4.24.19 |
01 Platform / Discovery |
University / Foundation |
Cancer |
Cancer (General) |
Other Tech |
Link |
| Prescient Medicine acquiring AutoGenomics |
4.23.19 |
08 Diagnostic – Any |
Acquisition |
Other |
Other |
Diagnostic-Other |
Link |
| RxGenomix contract service deal with Coriell Life |
4.23.19 |
10 Not Applicable |
Contract Service |
Not Applicable |
Not Applicable |
Other Tech |
Link |
| CareCentrix contract service deal with Turn-Key Health |
4.23.19 |
10 Not Applicable |
Contract Service |
Other |
Pain |
Unknown |
Link |
| TB Alliance commercialization deal with Mylan for two regimens |
4.18.19 |
09 Not Disclosed |
Sales / Co-Promotion Only |
Infectious |
Tuberculosis |
Small Molecule |
Link |
| Fibrocell development and commercialization deal with Castle for FCX-007 |
4.15.19 |
04 Phase II |
Dev and Commercial |
Dermatologic |
Genetic Diseases |
Gene Therapy |
Link |
| Gyroscope Acquiring Orbit |
4.11.19 |
10 Device – Any |
Acquisition |
Ophthalmic |
Ophthalmic (General) |
Device (General) |
Link |
| URGO purchasing Realm’s technology |
4.09.19 |
10 Not Applicable |
Platform, Product Purchase |
Other |
Wounds |
Other Tech |
Link |
| PhaseBio development and commercialization deal with ImmunoForge for PB1023 |
4.09.19 |
01 Platform / Discovery |
Dev and Commercial |
Cancer |
Unknown |
Not Applicable |
Link |
| Antengene research partnership with Baruch S. Blumberg Institute |
4.08.19 |
08 Diagnostic – Any |
R&D Only |
Cancer |
Hepatitis B Virus |
Diagnostic – Other |
Link |
| Dr. Reddy’s commercialization deal with Encore for SERNIVO, TRIANEX and PROMISEB |
4.02.19 |
06 Approved |
Sales / Co-Promotion Only |
Dermatologic |
Dermatologic (General) |
Formulation – Topical |
Link |
| Group K Diagnostics research partnership with Centers for Disease Control and Prevention |
3.26.19 |
08 Diagnostic – Any |
University / Foundation |
Infectious |
Infectious (General) |
Diagnostic – Lab Based Assay |
Link |
| Titan Medical research partnership with Teleflex for robotic ligation technology |
3.25.19 |
01 Platform / Discovery |
R&D Only |
Not Applicable |
Not Applicable |
Other Tech |
Link |
| Biofrontera acquiring Cutanea Life |
3.25.19 |
09 Not Disclosed |
Acquisition |
Dermatologic |
Dermatologic (General) |
Small Molecule |
Link |
| Knopp Biosciences research partnership with an undisclosed consortium |
3.20.19 |
04 Phase II |
R&D Only |
Pulmonary |
Asthma |
Small Molecule |
Link |
| NCCN grant to Taiho |
3.14.19 |
04 Phase II |
University / Foundation |
Cancer |
Solid tumors |
Small Molecule |
Link |
| Geisinger research partnership with OBERD for data integration tools |
3.12.19 |
01 Platform / Discovery |
University / Foundation |
Unknown |
Not Applicable |
Other Tech |
Link |
| NIH grant to Geisinger |
3.04.19 |
09 Not Disclosed |
University / Foundation |
Cardiovascular |
Cardiovascular (General) |
Other Tech |
Link |
| NIAID grant to VenatoRx |
2.28.19 |
09 Not Disclosed |
University / Foundation |
Infectious |
Gram-negative bacterial infection |
Other Tech |
Link |
| Roche acquiring Spark Therapeutics |
2.23.19 |
06 Approved |
Acquisition |
Ophthalmic |
Genetic Diseases |
Gene Therapy |
Link |
| Winstar Institute development and commercialization deal with Cullinan for VK-2019 |
1.30.19 |
09 Not Disclosed |
Dev and Commercial |
Cancer |
General within the TA or an unspecified indications |
Unknown |
Link |
| Knopp research partnership with Cincinnati to develop dexpramipexole |
1.16.19 |
04 Phase II |
University/Foundation |
Inflammation |
Asthma |
Small Molecule |
Link |
| Luminex development and commercialization deal with AllerGenis for diagnostic assay |
1.16.19 |
08 Diagnostic – Any |
Dev and Commercial |
Other |
Allergy |
Diagostic-Lab |
Link |
| GOG research partnership with OncoSec |
1.07.19 |
08 Diagnostic – Any |
GOG research partnership with OncoSec |
Cancer |
Cervical Cancer |
Gene Therapy |
Link |
| Integral research partnership with Daiichi for I-O therapeutics |
1.07.19 |
01 Platform / Discovery |
R&D Only |
Cancer |
General within the TA or an unspecified indication |
Protein |
Link |
| Knopp Biosciences research partnership with Baylor College of Medicine |
1.03.19 |
09 Not Disclosed |
University/Foundation |
Neurologic |
Epilepsy |
Unknown |
Link |
| Integral Molecular research partnership with Ono Pharmaceutical |
1.03.19 |
09 Not Disclosed |
R&D Only |
Unknown |
Unknown |
Biologic (General) |
Link |
| NCI grant to the University of Pennsylvania |
1.02.19 |
09 Not Disclosed |
University/Foundation |
Cancer |
Solid Tumors |
Immunotherapy / Cell Therapy |
Link |
| Windtree acquiring CVie |
12.21.18 |
09 Not Disclosed |
Acquisition |
Cardiovascular |
General within the TA or an unspecified indication |
Unknown |
Link |
| Ligand purchasing Palvella’s royalty rights to PTX-022 |
12.17.18 |
04 Phase II |
Royalty Stream Purchase |
Dermatologic |
General within the TA or an unspecified indication |
Formulation – Topical |
Link |
| Cabaletta Bio license deal with the University of Pennsylvania for CAAR T Cell Technology |
11.08.18 |
01 Platform / Discovery |
Dev and Commercial |
Autoimmune |
Pemphigus vulgaris (PV) |
Immunotherapy / Cell Therapy |
Link |
| Cabaletta Bio license deal with the University of Pennsylvania for CAAR T Cell Technology |
11.08.18 |
01 Platform / Discovery |
Dev and Commercial |
Autoimmune |
Pemphigus vulgaris (PV) |
Immunotherapy / Cell Therapy |
Link |
| BioNTech license deal with the University of Pennsylvania to develop Vaccine for infectious diseases |
11.05.18 |
01 Platform / Discovery |
University/Foundation |
Infectious |
General within the TA or an unspecified indication |
Vaccine |
Link |
| Yuhan development and commercialization deal with Janssen for Lazertinib |
11.05.18 |
03 Phase I |
Dev and Commercial |
Pulmonary |
Non-small cell lung cancer (NSCLC) |
Small Molecule |
Link |
| NIH grant to Integral Molecular |
11.01.18 |
10 Not Applicable |
University/Foundation |
Neurologic |
Alzheimer’s disease (AD) |
Proteomics |
Link |
| NIH grant to Integral Molecular |
11.01.18 |
10 Not Applicable |
University/Foundation |
Neurologic |
Alzheimer’s disease (AD) |
Proteomics |
Link |
| KemPharm commercialization deal with KVK for APADAZ |
10.30.18 |
06 Approved |
Sales / Co-Promotion Only |
Unknown |
Not Applicable |
Small Molecule |
Link |
| Gates Foundation grant to Inovio Pharmaceuticals |
10.17.18 |
01 Platform / Discovery |
University/Foundation |
Not Applicable |
Not Applicable |
Device (General) |
Link |
| Allergan development and commercialization deal with Aclaris for RHOFADE |
10.15.18 |
06 Approved |
Dev and Commercial |
Dermatologic |
Rosacea |
Formulation – Topical |
Link |
| Adynxx reverse merging with Alliqua |
10.12.18 |
07 Device – Any |
Reverse Merger |
Unknown |
Not Applicable |
Device (General) |
Link |
| Adynxx reverse merging with Alliqua |
10.12.18 |
07 Device – Any |
Reverse Merger |
Unknown |
Not Applicable |
Device (General) |
Link |
| Hemispherx clinical trial agreement with Roswell Park Cancer to evaluate Ampligen in combination with checkpoint inhibitors (CPIs) |
10.10.18 |
09 Not Disclosed |
University/Foundation |
Cancer |
Melanoma |
RNA |
Link |
| University of Pennsylvania research partnership with Amicus to develop AAV gene therapies |
10.08.18 |
01 Platform / Discovery |
University/Foundation |
Endocrine/Metabolic |
Pompe’s disease |
Gene Therapy |
Link |
| NIH commercialization deal with MTTI for Lutathera |
10.08.18 |
06 Approved |
Sales / Co-Promotion Only |
Neurologic |
Neuroendocrine tumors |
Other Tech |
Link |
| Teleflex acquiring Essential Medical |
10.04.18 |
07 Device – Any |
Acquisition |
Cardiovascular |
General within the TA or an unspecified indication |
Device (General) |
Link |
| NIA grant to Cognition Therapeutics to conduct Phase 2 SHINE study |
10.02.18 |
04 Phase II |
University/Foundation |
Neurologic |
Alzheimer’s disease (AD) |
Small Molecule |
Link |
| Wistar Institute spinning off Virion Therapeutics |
09.26.18 |
09 Not Disclosed |
Company Formation |
Infectious |
Viral Infection |
Vaccine |
Link |
| VenatoRx development and commercialization deal with Everest Medicines for cefepime/VNRX-5133 |
09.25.18 |
05 Phase III |
Dev and Commercial License |
Infectious |
Urinary tract infection |
Small Molecule |
Link |
| USFDA grant to Fibrocell |
09.25.18 |
09 Not Disclosed |
University/Foundation |
Dermatologic |
General within the TA or an unspecified indication |
Gene Therapy |
Link |
| NIDA grant to MEBIAS |
09.24.18 |
02 Preclinical / IND |
University/Foundation |
Pulmonary |
General within the TA or an unspecified indication |
Unknown |
Link |
| Clarus purchasing Galera’s royalty rights of GC4419 |
09.19.18 |
04 Phase II |
Royalty Stream Purchase |
Gastrointestinal |
General within the TA or an unspecified indication |
Unknown |
Link |
| Abzena development and commercialization deal with Tmunity for CAR-T engineered products |
09.19.18 |
01 Platform / Discovery |
Dev and Commercial |
Cancer |
Solid tumors |
Biologic (General) |
Link |
| Integral Molecular research partnership with Merus to develop monoclonal antibodies |
09.18.18 |
01 Platform / Discovery |
R&D Only |
Unknown |
Unknown |
Biologic (General) |
Link |
| TRIMEDX purchasing Aramark’s healthcare technologies business |
09.17.18 |
10 Not Applicable |
Business Unit Purchase |
Unknown |
Unknown |
Unknown |
Link |
| Johnson & Johnson acquiring EIT |
09.12.18 |
07 Device – Any |
Acquisition |
Musculoskeletal |
General within the TA or an unspecified indication |
Device (General) |
Link |
| Novo Nordisk research partnership with Ossianix with an option to license its VNAR antibodies |
09.04.18 |
01 Platform / Discovery |
Option to License |
Endocrine / Metabolic |
Diabetes |
Biologic (General) |
Link |
| Imalogix contract service deal with Guerbet |
08.13.18 |
01 Platform / Discovery |
Contract Service |
Unknown |
Not Applicable |
Other Tech |
Link |
| Context Therapeutics partnership with leading breast cancer investigators to evaluate Apristor |
08.08.18 |
04 Phase II |
University / Foundation |
Cancer |
Breast Cancer |
Small Molecule |
Link |
| University of Pennsylvania research partnership with Aevitas Therapeutics to evaluate gene therapy technology |
08.06.18 |
01 Platform / Discovery |
University / Foundation |
Unknown |
Not Applicable |
Gene Therapy |
Link |
| University of Pennsylvania development and commercialization deal with Neovasc for Tiara |
08.03.18 |
07 Device – Any |
Dev and Commercial |
Cardiovascular |
General within the TA or an unspecified indication |
Device (General) |
Link |
| Andor granted Lannett rights to commercialize generic Methylphenidate Hydrochloride ER |
08.03.18 |
10 Not Applicable |
Sales / Co-Promotion Only |
Unknown |
Unknown |
Small Molecule |
Link |
| Secant Group development and commercialization deal with Atvio to develop cell therapy |
07.30.18 |
01 Platform / Discovery |
Dev and Commercial License |
Endocrine / Metabolic |
Diabetes |
Immunotherapy / Cell Therapy |
Link |
| 360 Knee Systems development and commercialization deal with DePuy Synthes (Johnson & Johnson) for digital solutions for knee replacement |
07.23.18 |
07 Device – Any |
Dev and Commercial License |
Musculoskeletal |
Bone Repair |
Device (General) |
Link |
| Isogenica development and commercialization deal with Aro Biotherapeutics |
07.23.18 |
01 Platform / Discovery |
Dev and Commercial License |
Unknown |
Unknown |
Unknown |
Link |
| Botanix research partnership with University of Queensland to develop BTX 1801 |
07.19.18 |
09 Not Disclosed |
University / Foundation |
Dermatologic |
Bacterial Infection |
Other Tech |
Link |
| Janssen granted EUSA rights to commercialize SYLVANT |
07.18.18 |
06 Approved |
Sales / Co-Promotion Only |
Hematologic |
General within the TA or an unspecified indication |
Biologic (General) |
Link |
| MedPharm development and commercialization deal with Virpax for MedSpray technology |
06.21.18 |
01 Platform / Discovery |
Dev and Commercial License |
Other |
Pain |
Unknown |
Link |
| University of Pennsylvania research partnership with Ophthotech |
06.07.18 |
02 Preclinical / IND |
University / Foundation |
Ophthalmic |
Retinitis |
Gene Therapy |
Link |
| LipoCure research partnership with Virpax |
06.04.18 |
02 Preclinical / IND |
University / Foundation |
Ophthalmic |
Retinitis |
Gene Therapy |
Link |
| University of Pennsylvania research partnership with Ophthotech |
06.07.18 |
02 Preclinical / IND |
University / Foundation |
Ophthalmic |
Retinitis |
Gene Therapy |
Link |
| LipoCure research partnership with Virpax |
06.04.18 |
02 Preclinical / IND |
R&D Only |
Other |
Pain |
Formulation – Liposomal |
Link |
| DePuy purchasing J&J’s surgical impactor technology including ME1000 |
05.14.18 |
07 Device – Any |
Platform, Product Purchase |
Other |
Not Applicable |
Device (General) |
Link |
| Aeterna Zentaris development and commercialization deal with Strongbridge Biopharma |
05.08.18 |
06 Approved |
Dev and Commercial License |
Endocrine / Metabolic |
Growth hormone deficiency |
Formulation – Oral |
Link |
| Regeneron research partnership with Inovio |
05.08.18 |
03 Phase I |
R&D Only |
Neurologic |
Brain Cancer |
Antibody |
Link |
| Lannett purchasing Endo’s generics portfolio |
05.07.18 |
06 Approved |
Business Unit Purchase |
Unknown |
Not Applicable |
Other Tech |
Link |
| Janssen Biotech acquiring Benevir Biopharm |
05.03.18 |
02 Preclinical / IND |
Acquisition |
Cancer |
Not Applicable |
Immunotherapy / Cell Therapy |
Link |
|
|
|
|
|
|
|
Link |
| Trevena development and commercialization deal with Jiangsu Nhwa Pharmaceutical |
05.01.18 |
09 Not Disclosed |
Dev and Commercial License |
Other |
Pain |
Small Molecule |
Link |
| Jazz purchasing Spark Therapeutics’s Priority Review Voucher |
04.30.18 |
10 Not Applicable |
Platform, Product Purchase |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| CEPI grant to Inovio Pharmaceuticals |
04.11.18 |
02 Preclinical / IND |
University / Foundation |
Infectious |
General within the TA or an unspecified indication |
Vaccine |
Link |
| Morphotek granted Bliss rights to its Eribulin-Linker Payload to develop antibody drug conjugates (ADC) |
04.09.18 |
01 Platform / Discovery |
Dev and Commercial License |
Cancer |
Not Applicable |
Antibody |
Link |
| Aclaris development and commercialization deal with Cipher |
04.06.18 |
06 Approved |
Dev and Commercial License |
Dermatologic |
Not Applicable |
Formulation – Topical |
Link |
| Innate Biologics research partnership with Wistar |
03.21.18 |
01 Platform / Discovery |
University / Foundation |
Inflammation |
Unknown |
Unknown |
Link |
| ImmunoRestoration license deal with University of Pennsylvania |
03.14.18 |
01 Platform / Discovery |
University / Foundation |
Cancer |
Breast Cancer |
Vaccine |
Link |
| Hemispherx Biopharma research partnership with UNMC |
03.14.18 |
09 Not Disclosed |
University / Foundation |
Cancer |
Pancreatic Cancer |
Vaccine |
Link |
| Windtree research partnership with Eleison |
03.12.18 |
04 Phase II |
R&D Only |
Cancer |
Lung Cancer |
Immunotherapy |
Link |
| Aevi Genomic granted Kyowa Hakko an option to license the development and commercialization of its monoclonal antibody |
03.07.18 |
02 Preclinical / IND |
Option to License |
Unknown |
Unknown |
Antibody |
Link |
| Onconova commercialization deal with Pint for Rigosertib in Latin America |
03.05.18 |
05 Phase III |
Sales / Co-Promotion Only |
Cancer |
Myelodysplastic syndrome (MDS) |
Small Molecule |
Link |
| NIH grant to PhaseBio |
02.27.18 |
03 Phase I |
University / Foundation |
Cardiovascular |
Hypertension |
Protein |
Link |
| Boston Therapeutics acquiring CureDM |
02.19.18 |
04 Phase II |
Acquisition |
Endocrine / Metabolic |
Not Applicable |
Peptide |
Link |
| Spark Therapeutics development and commercialization deal with Novartis |
01.24.18 |
05 Phase III |
Dev and Commercial License |
Ophthalmic |
General within the TA or an unspecified indication |
Gene Therapy |
Link |
| Torrent Pharma acquiring Bio-Pharm |
01.18.18 |
10 Not Applicable |
Acquisition |
Not Applicable |
Not Applicable |
Not Applicable |
Link |
| Context Therapeutics purchasing Arno’s Apristor |
01.16.18 |
04 Phase II |
Platform, Product Purchase |
Cancer |
Breast Cancer |
Small Molecule |
Link |
| Oncoceutics development and commercialization deal with Frontida BioPharm for ONC201 |
01.16.18 |
04 Phase II |
Dev and Commercial License |
Cancer |
General within the TA or an unspecified indication |
Small Molecule |
Link |
| Inovio research partnership with Parker Institute for Cancer Immunotherapy |
01.09.18 |
03 Phase I |
University / Foundation |
Cancer |
Bladder Cancer |
Immunotherapy / Cell Therapy |
Link |
| J&J license deal with University of Pennsylvania |
01.05.18 |
01 Platform / Discovery |
University / Foundation |
Neurologic |
Alzheimer’s disease (AD) |
Gene Therapy |
Link |
| Koch Institute for Integrative Cancer Research research partnership with Janssen |
01.05.18 |
01 Platform / Discovery |
R&D Only |
Cancer |
Lung cancer |
Not Applicable |
Link |
| Mindera research partnership with Janssen |
01.05.18 |
07 Device – Any |
R&D Only |
Inflammation |
Inflammatory disease |
Device (General) |
Link |
| WinterLight Labs research partnership with Janssen to use voice analysis in Alzheimer’s detection |
01.05.18 |
01 Platform / Discovery |
R&D Only |
Neurologic |
Alzheimer’s disease (AD) |
Digital Health |
Link |
| Treventis development and commercialization deal with Servier |
01.04.18 |
09 Not Disclosed |
Dev and Commercial License |
Neurologic |
Alzheimer’s disease (AD) |
Protein |
Link |
| DTRA grant to VenatoRx |
01.04.18 |
10 Not Applicable |
University / Foundation |
Infectious |
Bacterial infection |
Not Applicable |
Link |
|
